NF2 and meningioma: Nassiri et al. used copy number variation analysis, somatic point mutations, methylation profiles, and messenger RNA abundance of 121 meningiomas, creating four molecular subtypes, immunogenic, benign NF2 wild-type, hypermetabolic, and proliferative, allowing them to better predict the outcomes compared to the 2016 WHO classification of CNS tumors [112].